{"protocolSection":{"identificationModule":{"nctId":"NCT03055000","orgStudyIdInfo":{"id":"170059"},"secondaryIdInfos":[{"id":"17-I-0059","type":"OTHER","domain":"NIAID"}],"organization":{"fullName":"National Institutes of Health Clinical Center (CC)","class":"NIH"},"briefTitle":"Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine","officialTitle":"Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine"},"statusModule":{"statusVerifiedDate":"2018-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-02-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-12-28","type":"ACTUAL"},"completionDateStruct":{"date":"2018-12-28","type":"ACTUAL"},"studyFirstSubmitDate":"2017-02-14","studyFirstSubmitQcDate":"2017-02-14","studyFirstPostDateStruct":{"date":"2017-02-16","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-03-05","resultsFirstSubmitQcDate":"2020-07-21","resultsFirstPostDateStruct":{"date":"2020-08-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-08-03","lastUpdatePostDateStruct":{"date":"2020-08-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"National Institute of Allergy and Infectious Diseases (NIAID)","class":"NIH"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Background:\n\nMosquitos carry diseases that cause major health problems and death worldwide. The AGS-v vaccine targets proteins in mosquito saliva. This may help prevent many mosquito-borne diseases. It might also reduce the lifespan of the mosquito that bites the vaccinated person.\n\nObjective:\n\nTo see if the AGS-v vaccine is safe in humans and how it affects the immune system.\n\nEligibility:\n\nHealthy adults ages 18-50\n\nDesign:\n\nParticipants will be screened another study.\n\nParticipants will be randomly assigned to get either the vaccine with a booster vaccine, the vaccine without the booster, or a placebo. These are given through a needle in the upper arm.\n\nParticipants will have visits that include medical history, physical exam, and blood and urine tests:\n\nBaseline: They will get the vaccine and be monitored for 2 hours.\n\nFollow-up visits 1 and 2 weeks after baseline.\n\nVisit 3 weeks after baseline: They will get the booster and be monitored for 2 hours.\n\nFollow-up visits 1 and 2 weeks after booster visit.\n\nVisit 3-5 weeks after booster visit: This includes mosquito feeding. Mosquitos grown in the lab will be allowed to bite the arm. Blood will be drawn 4 times in the 3 hours after the feeding.\n\nPhone follow-up a few days after the mosquito feeding.\n\nAfter the feeding visit, 5 follow-up visits about every 2 months\n\nParticipants will keep a symptom diary for 7 days after each vaccine. They will record their temperature. They will measure any redness around the injection site. They will document and if possible photograph any mosquito bites they get.","detailedDescription":"Mosquito-borne diseases continue to cause significant morbidity and mortality worldwide despite on-going control efforts. In 2015, there were \\>200 million cases of malaria worldwide, causing nearly half a million deaths, with most of the deaths occurring among children under the age of 5 years. Mosquitos also transmit arboviruses, including dengue, yellow fever, West Nile virus, chikungunya, Rift Valley fever, Japanese encephalitis, and Zika virus. The current new outbreak of Zika virus in Central and South America, as well as the Caribbean, serves as a reminder of how quickly these viruses can spread and how difficult they can be to control.\n\nIn this protocol we plan to perform a Phase I study of a novel universal mosquito-borne disease vaccine. Through modulation of the immune system after a mosquito feeding, this vaccine targets the vector saliva and may provide prophylaxis against multiple arboviral and protozoal diseases. In addition the vaccine potentially leads to a reduced mosquito lifespan after feeding therefore also reducing transmission of these diseases.\n\nIn this protocol we hope to demonstrate the safety of this vaccine similar to SEEK s other peptide based vaccines Flu-v and HIV-v that have been found to have very good safety profiles in previous Phase I trials. We also hope to demonstrate immunomodulation after a controlled clean Aedes aegypti mosquito feeding to demonstrate proof of concept efficacy of the vaccine. With the current rise of Zika in the Americas and the threat of local mosquito transmission in the U.S. and the rest of the world, a successful universal mosquito-borne disease vaccine offers the benefit of targeting this emerging disease as well as the many established infections such as dengue and malaria that make dealing with this newly emerging epidemic a challenge."},"conditionsModule":{"conditions":["Mosquito-Borne Disease"],"keywords":["Mosquito-Borne Diseases","Universal Mosquito Vaccine","Mosquito Transmission","Vector Borne Viruses","Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":49,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"AGS-v","type":"EXPERIMENTAL","description":"AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21","interventionNames":["Biological: AGS-v"]},{"label":"AGS-v with adjuvant","type":"EXPERIMENTAL","description":"ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21","interventionNames":["Biological: AGS-v + adjuvant"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"WFI (0.5mL) on Day 0 and Day 21","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"AGS-v","description":"AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21","armGroupLabels":["AGS-v"]},{"type":"BIOLOGICAL","name":"AGS-v + adjuvant","description":"ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21","armGroupLabels":["AGS-v with adjuvant"]},{"type":"OTHER","name":"Placebo","description":"WFI (0.5mL) on Day 0 and Day 21","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"AEs Grade 3 or Higher","description":"Grade 3 or higher adverse events identified within 1 year after 2 vaccinations 21 days apart.","timeFrame":"1 year after vaccination (study duration)"},{"measure":"GM-CSF Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"21 days after last vaccination"},{"measure":"IL-10 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"21 days after last vaccination"},{"measure":"IL-1B Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"21 days after last vaccination"},{"measure":"IL-2 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"21 days after last vaccination"},{"measure":"IL-4 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"21 days after last vaccination"},{"measure":"IL-5 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"21 days after last vaccination"},{"measure":"Interferon-gamma Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"21 days after last vaccination"},{"measure":"Number of Subjects With 1 or More Aes","description":"Percent of people with an AE","timeFrame":"1 year after vaccination (study duration)"},{"measure":"Number of Subjects With 1 or More Grade 3 or Higher AE","description":"Percent of people with a Grade 3 or higher AE","timeFrame":"1 year after vaccination (study duration)"},{"measure":"TNF-a Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"21 days after last vaccination"},{"measure":"Total AGS-v Specific Immunoglobulin","description":"Total AGS-v specific immunoglobulin measured in serum 14 days after the first and/or second vaccination.","timeFrame":"21 days after last vaccination"}],"secondaryOutcomes":[{"measure":"GM-CSF Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"60 days after Day 42 Mosquito Feeding"},{"measure":"IL-10 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"60 days after Day 42 Mosquito Feeding"},{"measure":"IL-1B Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"60 days after Day 42 Mosquito Feeding"},{"measure":"IL-2 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"60 days after Day 42 Mosquito Feeding"},{"measure":"IL-4 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"60 days after Day 42 Mosquito Feeding"},{"measure":"IL-5 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"60 days after Day 42 Mosquito Feeding"},{"measure":"Interferon-gamma Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"60 days after Day 42 Mosquito Feeding"},{"measure":"Number of Adults Developed From 100 Eggs","description":"Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination","timeFrame":"Day 42 Mosquito feeding"},{"measure":"Number of Eggs Laid","description":"Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination","timeFrame":"Day 42 Mosquito feeding"},{"measure":"Number of Pupae Hatched of 100 Eggs","description":"Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination","timeFrame":"Day 42 Mosquito feeding"},{"measure":"Percent of Eggs That Developed Into Pupae","description":"Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination","timeFrame":"Day 42 Mosquito feeding"},{"measure":"Percent of Pupae That Developed Into Adults","description":"Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination","timeFrame":"Day 42 Mosquito feeding"},{"measure":"TNF-a Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","timeFrame":"60 days after Day 42 Mosquito Feeding"},{"measure":"Total AGS-v Specific Immunoglobulin","description":"Total AGS-v specific immunoglobulin measured in serum after the first and/or second vaccination.","timeFrame":"60 days after Day 42 Mosquito Feeding"}]},"eligibilityModule":{"eligibilityCriteria":"-INCLUSION CRITERIA:\n\n1. Healthy women and men who are greater than or equal to 18 and less than or equal to 50 years of age.\n2. Willingness to complete all study visits and comply with all study requirements.\n3. A male subject is eligible for the study if he agrees to practicing abstinence or using a condom with spermicide plus an acceptable form of contraception (see inclusion criteria 4) being used by any female partner from 4 weeks before study start to 12 weeks after the second vaccine administration.\n4. A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:\n\n   * Of non-child bearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year).\n   * Of childbearing potential but agrees to practice effective contraception or abstinence for 4 weeks prior to study initiation through 12 weeks after the second vaccine administration. Acceptable methods of contraception include a male partner who is sterile and is the sole sexual partner of the female participant or a male partner who uses a condom with spermicide plus 1 or more of the following: 1) implants of levonorgestrel; 2) injectable progestogen; 3) an intrauterine device with a documented failure rate of \\<1%; 4) oral contraceptives; and 5) double barrier method including diaphragm.\n5. Willing to have samples stored for future research (including genetic research).\n6. Agrees to abstain from alcohol intake for 24 hours prior to each study visit.\n7. Agrees to not donate blood or blood products throughout the study.\n\nEXCLUSION CRITERIA:\n\n1. Participant has any underlying or current medical condition, which, in the opinion of the Investigator, would interfere with the participation in the study.\n2. Individual with body mass index (BMI) less than or equal to 18 and greater than or equal to 40.\n3. Participants who have a clinically significant (as determined by the PI) baseline Grade 1 or greater toxicity, or any Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity table.\n4. Receipt of blood or blood products (including immunoglobulins) within 3 months prior to enrollment.\n5. Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is greater) prior to enrollment.\n6. Receipt of any unlicensed vaccine within 6 months prior to enrollment.\n7. Self-reported or known history of alcoholism or drug abuse within 6 months prior to enrollment, or positive urine/serum test for drugs of abuse at screening\n8. Self-reported or known history of psychiatric or psychological issues that require treatment and are deemed by the PI to be a contraindication to protocol participation.\n9. History of a previous severe allergic reaction with generalized urticaria, angioedema, anaphylaxis or anaphylactoid reaction.\n10. Any condition or event that, in the judgment of the PI, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent.\n11. Has a known allergy to any of the components of the vaccine.\n12. Has a history of severe immunization reaction.\n13. Has a severe allergic reaction to mosquito bites","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Matthew J Memoli, M.D.","affiliation":"National Institute of Allergy and Infectious Diseases (NIAID)","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"National Institutes of Health Clinical Center","city":"Bethesda","state":"Maryland","zip":"20892","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}}]},"referencesModule":{"references":[{"pmid":"8814051","type":"BACKGROUND","citation":"Peng Z, Yang M, Simons FE. Immunologic mechanisms in mosquito allergy: correlation of skin reactions with specific IgE and IgG antibodies and lymphocyte proliferation response to mosquito antigens. Ann Allergy Asthma Immunol. 1996 Sep;77(3):238-44. doi: 10.1016/S1081-1206(10)63262-0."},{"pmid":"9347958","type":"BACKGROUND","citation":"Sidjanski S, Vanderberg JP. Delayed migration of Plasmodium sporozoites from the mosquito bite site to the blood. Am J Trop Med Hyg. 1997 Oct;57(4):426-9. doi: 10.4269/ajtmh.1997.57.426."},{"pmid":"2880553","type":"BACKGROUND","citation":"Ribeiro JM. Role of saliva in blood-feeding by arthropods. Annu Rev Entomol. 1987;32:463-78. doi: 10.1146/annurev.en.32.010187.002335. No abstract available."},{"pmid":"32534628","type":"DERIVED","citation":"Manning JE, Oliveira F, Coutinho-Abreu IV, Herbert S, Meneses C, Kamhawi S, Baus HA, Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Athota R, Reed S, Mateja A, Hunsberger S, James E, Pleguezuelos O, Stoloff G, Valenzuela JG, Memoli MJ. Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial. Lancet. 2020 Jun 27;395(10242):1998-2007. doi: 10.1016/S0140-6736(20)31048-5. Epub 2020 Jun 11."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"FG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses givemn 21 days apart"},{"id":"FG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"16"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"16"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"BG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"BG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"49"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"49"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"30"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"19"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"10"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"39"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"18"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"23"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"6"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"AEs Grade 3 or Higher","description":"Grade 3 or higher adverse events identified within 1 year after 2 vaccinations 21 days apart.","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"adverse events","timeFrame":"1 year after vaccination (study duration)","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","lowerLimit":"0.16","upperLimit":"0.63"},{"groupId":"OG001","value":"0.65","lowerLimit":"0.23","upperLimit":"0.93"},{"groupId":"OG002","value":"0.63","lowerLimit":"0.22","upperLimit":"0.89"}]}]}]},{"type":"PRIMARY","title":"GM-CSF Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"21 days after last vaccination","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.106","spread":"0.285"},{"groupId":"OG001","value":"3.76","spread":"6.05"},{"groupId":"OG002","value":"1.101","spread":"1.01"}]}]}]},{"type":"PRIMARY","title":"IL-10 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"21 days after last vaccination","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.983","spread":"0.048"},{"groupId":"OG001","value":"1.088","spread":"0.169"},{"groupId":"OG002","value":"0.976","spread":"0.055"}]}]}]},{"type":"PRIMARY","title":"IL-1B Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"21 days after last vaccination","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.009","spread":"0.119"},{"groupId":"OG001","value":"0.964","spread":"0.105"},{"groupId":"OG002","value":"0.946","spread":"0.107"}]}]}]},{"type":"PRIMARY","title":"IL-2 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"21 days after last vaccination","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.173","spread":"0.421"},{"groupId":"OG001","value":"1.225","spread":"0.372"},{"groupId":"OG002","value":"1.115","spread":"0.293"}]}]}]},{"type":"PRIMARY","title":"IL-4 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"21 days after last vaccination","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"0.027"},{"groupId":"OG001","value":"1.018","spread":"0.047"},{"groupId":"OG002","value":"0.991","spread":"0.027"}]}]}]},{"type":"PRIMARY","title":"IL-5 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"21 days after last vaccination","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.267","spread":"0.664"},{"groupId":"OG001","value":"4.389","spread":"13.32"},{"groupId":"OG002","value":"1.022","spread":"0.091"}]}]}]},{"type":"PRIMARY","title":"Interferon-gamma Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"21 days after last vaccination","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"0.568"},{"groupId":"OG001","value":"1.613","spread":"0.764"},{"groupId":"OG002","value":"1.103","spread":"0.307"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With 1 or More Aes","description":"Percent of people with an AE","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"1 year after vaccination (study duration)","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"15"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With 1 or More Grade 3 or Higher AE","description":"Percent of people with a Grade 3 or higher AE","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"1 year after vaccination (study duration)","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}]}]},{"type":"PRIMARY","title":"TNF-a Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"21 days after last vaccination","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.995","spread":"0.104"},{"groupId":"OG001","value":"1.255","spread":"0.573"},{"groupId":"OG002","value":"0.993","spread":"0.078"}]}]}]},{"type":"PRIMARY","title":"Total AGS-v Specific Immunoglobulin","description":"Total AGS-v specific immunoglobulin measured in serum 14 days after the first and/or second vaccination.","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"IU/mL","timeFrame":"21 days after last vaccination","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9903","spread":"0.373"},{"groupId":"OG001","value":"4.3115","spread":"5.08"},{"groupId":"OG002","value":"1.0232","spread":"1.42"}]}]}]},{"type":"SECONDARY","title":"GM-CSF Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"60 days after Day 42 Mosquito Feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.198","spread":"1.289"},{"groupId":"OG001","value":"1.8","spread":"5.806"},{"groupId":"OG002","value":"0.902","spread":"0.296"}]}]}]},{"type":"SECONDARY","title":"IL-10 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"60 days after Day 42 Mosquito Feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.376","spread":"2.029"},{"groupId":"OG001","value":"1.749","spread":"1.687"},{"groupId":"OG002","value":"0.813","spread":"0.206"}]}]}]},{"type":"SECONDARY","title":"IL-1B Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"60 days after Day 42 Mosquito Feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.905","spread":"0.546"},{"groupId":"OG001","value":"0.955","spread":"0.281"},{"groupId":"OG002","value":"0.758","spread":"0.268"}]}]}]},{"type":"SECONDARY","title":"IL-2 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"60 days after Day 42 Mosquito Feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.027","spread":"0.583"},{"groupId":"OG001","value":"1.036","spread":"0.138"},{"groupId":"OG002","value":"0.98","spread":"0.221"}]}]}]},{"type":"SECONDARY","title":"IL-4 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"60 days after Day 42 Mosquito Feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.034","spread":"0.254"},{"groupId":"OG001","value":"1.061","spread":"0.157"},{"groupId":"OG002","value":"0.915","spread":"0.211"}]}]}]},{"type":"SECONDARY","title":"IL-5 Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"60 days after Day 42 Mosquito Feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.233","spread":"4.085"},{"groupId":"OG001","value":"3.113","spread":"5.993"},{"groupId":"OG002","value":"0.933","spread":"0.119"}]}]}]},{"type":"SECONDARY","title":"Interferon-gamma Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"60 days after Day 42 Mosquito Feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.577","spread":"3.954"},{"groupId":"OG001","value":"2.004","spread":"4.795"},{"groupId":"OG002","value":"0.594","spread":"0.792"}]}]}]},{"type":"SECONDARY","title":"Number of Adults Developed From 100 Eggs","description":"Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Adult aedes aegypti mosquitoes","timeFrame":"Day 42 Mosquito feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.13","spread":"14.07"},{"groupId":"OG001","value":"75.25","spread":"13.55"},{"groupId":"OG002","value":"78.53","spread":"9.52"}]}]}]},{"type":"SECONDARY","title":"Number of Eggs Laid","description":"Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Eggs","timeFrame":"Day 42 Mosquito feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"706","spread":"123.75"},{"groupId":"OG001","value":"673.88","spread":"221.29"},{"groupId":"OG002","value":"663","spread":"165.51"}]}]}]},{"type":"SECONDARY","title":"Number of Pupae Hatched of 100 Eggs","description":"Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Number of hatched pupae","timeFrame":"Day 42 Mosquito feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.93","spread":"13.08"},{"groupId":"OG001","value":"79.62","spread":"14.86"},{"groupId":"OG002","value":"81.93","spread":"9.08"}]}]}]},{"type":"SECONDARY","title":"Percent of Eggs That Developed Into Pupae","description":"Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of eggs","timeFrame":"Day 42 Mosquito feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.59","spread":"3.26"},{"groupId":"OG001","value":"15.56","spread":"13.58"},{"groupId":"OG002","value":"13.76","spread":"6.49"}]}]}]},{"type":"SECONDARY","title":"Percent of Pupae That Developed Into Adults","description":"Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of pupae","timeFrame":"Day 42 Mosquito feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.12","spread":"12.8"},{"groupId":"OG001","value":"94.96","spread":"6.86"},{"groupId":"OG002","value":"95.77","spread":"2.88"}]}]}]},{"type":"SECONDARY","title":"TNF-a Cytokine Level as Measured by Luminex","description":"Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"60 days after Day 42 Mosquito Feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.392","spread":"3.464"},{"groupId":"OG001","value":"1.382","spread":"5.867"},{"groupId":"OG002","value":"0.707","spread":"0.554"}]}]}]},{"type":"SECONDARY","title":"Total AGS-v Specific Immunoglobulin","description":"Total AGS-v specific immunoglobulin measured in serum after the first and/or second vaccination.","populationDescription":"All subjects who received vaccination","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"IU/mL","timeFrame":"60 days after Day 42 Mosquito Feeding","groups":[{"id":"OG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart"},{"id":"OG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0077","spread":"0.29"},{"groupId":"OG001","value":"3.6537","spread":"4.45"},{"groupId":"OG002","value":"1.2011","spread":"1.27"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"1 year","eventGroups":[{"id":"EG000","title":"AGS-v","description":"825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart","deathsNumAffected":0,"deathsNumAtRisk":16,"seriousNumAffected":0,"seriousNumAtRisk":16,"otherNumAffected":16,"otherNumAtRisk":16},{"id":"EG001","title":"AGS-v With Adjuvant","description":"825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart","deathsNumAffected":0,"deathsNumAtRisk":17,"seriousNumAffected":0,"seriousNumAtRisk":17,"otherNumAffected":17,"otherNumAtRisk":17},{"id":"EG002","title":"Placebo","description":"Placebo 2 doses given 21 days apart","deathsNumAffected":0,"deathsNumAtRisk":16,"seriousNumAffected":0,"seriousNumAtRisk":16,"otherNumAffected":15,"otherNumAtRisk":16}],"otherEvents":[{"term":"Eosinophilia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Lymph node pain","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":16},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":16}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Chills","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":16},{"groupId":"EG001","numAffected":8,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":16}]},{"term":"Injection site erythema","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":16},{"groupId":"EG001","numAffected":8,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":16}]},{"term":"Injection site induration","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Injection site pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":16},{"groupId":"EG001","numAffected":9,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":16}]},{"term":"Injection site pruritus","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":16},{"groupId":"EG001","numAffected":7,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Injection site swelling","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":9,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":7,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":16}]},{"term":"Swelling","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":16},{"groupId":"EG001","numAffected":16,"numAtRisk":17},{"groupId":"EG002","numAffected":15,"numAtRisk":16}]},{"term":"Tenderness","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Campylobacter infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Hordeolum","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Influenza","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Laryngitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Rhinitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Sinusitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Vulvovaginal candidiasis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":16}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Blood creatine phosphokinase","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":16},{"groupId":"EG001","numAffected":5,"numAtRisk":17},{"groupId":"EG002","numAffected":7,"numAtRisk":16}]},{"term":"Blood creatinine increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Blood urea increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Eosinophil count increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":16},{"groupId":"EG001","numAffected":6,"numAtRisk":17},{"groupId":"EG002","numAffected":5,"numAtRisk":16}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Lymphocyte count increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":16},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":16}]},{"term":"White blood cell count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":16}]},{"term":"White blood cell count increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"White blood cells urine positive","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":16}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":16},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":16}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":16}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":16}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":16}]},{"term":"Vitamin D deficiency","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":4,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":16},{"groupId":"EG001","numAffected":7,"numAtRisk":17},{"groupId":"EG002","numAffected":5,"numAtRisk":16}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":16},{"groupId":"EG001","numAffected":8,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":16}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":16}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":16},{"groupId":"EG001","numAffected":15,"numAtRisk":17},{"groupId":"EG002","numAffected":15,"numAtRisk":16}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":16}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":16}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Skin induration","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Tooth extraction","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]},{"term":"Systolic hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":0,"numAtRisk":16}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Memoli, Matthew","organization":"National Institute of Allergy and Infectious Diseases","email":"mm982v@nih.gov","phone":"+1 301 443 5971"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-02-09","uploadDate":"2020-03-04T14:31","filename":"Prot_SAP_000.pdf","size":942216},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2018-04-02","uploadDate":"2020-03-04T14:49","filename":"ICF_001.pdf","size":169976}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D000096724","term":"Mosquito-Borne Diseases"}],"ancestors":[{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"D000277","term":"Adjuvants, Pharmaceutic"}],"ancestors":[{"id":"D010592","term":"Pharmaceutic Aids"},{"id":"D004364","term":"Pharmaceutical Preparations"},{"id":"D020313","term":"Specialty Uses of Chemicals"},{"id":"D020164","term":"Chemical Actions and Uses"}]}},"hasResults":true}